首页> 美国卫生研究院文献>The FASEB Journal >Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury
【2h】

Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury

机译:将血栓调节蛋白靶向循环红细胞可增强其在内毒素血症和缺血再灌注损伤模型中的保护作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Endothelial thrombomodulin (TM) regulates coagulation and inflammation via several mechanisms, including production of activated protein C (APC). Recombinant APC and soluble fragments of TM (sTM) have been tested in settings associated with insufficiency of the endogenous TM/APC pathway, such as sepsis. We previously designed a fusion protein of TM [single-chain variable fragment antibody (scFv)/TM] targeted to red blood cells (RBCs) to improve pharmacokinetics and antithrombotic effects without increasing bleeding. Here, scFv/TM was studied in mouse models of systemic inflammation and ischemia-reperfusion injury. Injected concomitantly with or before endotoxin, scFv/TM provided more potent protection against liver injury and release of pathological mediators than sTM, showing similar efficacy at up to 50-fold lower doses. scFv/TM provided protection when injected after endotoxin, whereas sTM did not, and augmented APC production by thrombin ∼50-fold more than sTM. However, scFv/TM injected after endotoxin did not reduce thrombin/antithrombin complexes; nor did antibodies that block APC anticoagulant activity suppress the prophylactic anti-inflammatory effect of scFv/TM. Therefore, similar to endogenous TM, RBC-anchored scFv/TM activates several protective pathways. Finally, scFv/TM was more effective at reducing cerebral infarct volume and alleviated neurological deficits than sTM after cerebral ischemia/reperfusion injury. These results indicate that RBC-targeted scFv/TM exerts multifaceted cytoprotective effects and may find utility in systemic and focal inflammatory and ischemic disorders.—Carnemolla, R., Villa, C. H., Greineder, C. F., Zaitseva, S., Patel, K. R., Kowalska, M. A., Atochin, D. N., Cines, D. B., Siegel, D. L., Esmon, C. T., Muzykantov, V. R. Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury
机译:内皮血栓调节蛋白(TM)通过多种机制调节凝血和炎症,包括活化蛋白C(APC)的产生。重组APC和TM(sTM)的可溶性片段已在与内源性TM / APC途径(如败血症)不足相关的环境中进行了测试。我们先前设计了针对红细胞(RBC)的TM [单链可变片段抗体(scFv)/ TM]融合蛋白,以改善药代动力学和抗血栓形成作用,而不会增加出血。在这里,scFv / TM在全身性炎症和局部缺血再灌注损伤的小鼠模型中进行了研究。与内毒素同时或之前注射,scFv / TM比sTM提供更有效的抗肝损伤和病理介质释放的保护,在低至50倍的低剂量下显示出相似的功效。内毒素注射后,scFv / TM可提供保护,而sTM则不提供,并且凝血酶的APC产量比sTM多50倍。但是,内毒素注射后的scFv / TM不能减少凝血酶/抗凝血酶复合物。阻断APC抗凝活性的抗体也不能抑制scFv / TM的预防性抗炎作用。因此,类似于内源性TM,RBC锚定的scFv / TM激活了几种保护途径。最后,与缺血性脑缺血/再灌注损伤后的sTM相比,scFv / TM在减少脑梗死体积和减轻神经功能缺损方面更有效。这些结果表明,针对RBC的scFv / TM发挥了多方面的细胞保护作用,并可能在全身性和局灶性炎性和缺血性疾病中发挥作用。-Carnemolla,R.,Villa,CH,Greineder,CF,Zaitseva,S.,Patel,KR, Kowalska,MA,Atochin,DN,Cines,DB,Siegel,DL,Esmon,CT,Muzykantov,VR将血栓调节蛋白靶向循环中的红细胞可增强其在内毒素血症和缺血再灌注损伤模型中的保护作用

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号